WP
VNDA icon

Woodline Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Woodline Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-207,666
Closed -$1.43M – 1153
2026
Q1 		$1.43M Buy
+207,666
New +$1.6M 0.01% 836

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's VNDA Position: Q2 2026 in Review

Woodline Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 207,666 shares — an estimated $1.43M sold.

Woodline Partners first reported a position in VNDA in Q1 2026 and held it in 1 quarter. The position peaked at $1.43M in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Woodline Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 207,666 Vanda Pharmaceuticals shares in Q2 2026, an estimated $1.43M.
  • Woodline Partners first reported a position in Vanda Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Woodline Partners's Vanda Pharmaceuticals position peaked at $1.43M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.